Safety analysis of inactivated SARS-CoV-2 vaccine (Vero cells) during emergency vaccination in Hefei

ZHU Li-wei; CHEN Guo-jie; JIANG Ling; MA Chun-yu

doi:10.16462/j.cnki.zhjbkz.2021.07.012

Volume 25 Issue 7

Aug. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(7): 802-805

ZHU Li-wei, CHEN Guo-jie, JIANG Ling, MA Chun-yu. Safety analysis of inactivated SARS-CoV-2 vaccine (Vero cells) during emergency vaccination in Hefei[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(7): 802-805. doi: 10.16462/j.cnki.zhjbkz.2021.07.012

Citation:

ZHU Li-wei, CHEN Guo-jie, JIANG Ling, MA Chun-yu. Safety analysis of inactivated SARS-CoV-2 vaccine (Vero cells) during emergency vaccination in Hefei[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(7): 802-805. doi: 10.16462/j.cnki.zhjbkz.2021.07.012

Citation:

PDF( 810 KB)

Safety analysis of inactivated SARS-CoV-2 vaccine (Vero cells) during emergency vaccination in Hefei

doi: 10.16462/j.cnki.zhjbkz.2021.07.012

1.
Hefei First People' s Hospital, Hefei 230031, China
2.
Binhu Hospital of Hefei, Hefei 230601, China
3.
Baohe District Center for Disease Control and Prevention, Hefei 230051, China
4.
Luyang District Center for Disease Control and Prevention, Hefei 230061, China

More Information

Corresponding author: ZHU Li-wei, E-mail: 87407634@qq.com
Received Date: 2021-02-24
Rev Recd Date: 2021-06-07

Available Online: 2021-08-13

Publish Date: 2021-07-10

Abstract

Abstract

Objective To study the safety of inactivated SARS-CoV-2 vaccine (Vero cells) (SARS-CoV-2 vaccine) in Hefei during the emergency vaccination period, and to provide reference for the promotion and vaccination of this vaccine in the whole population in the later period. Methods A total of 19 vaccination clinics in Hefei were selected as active monitoring sites for immunization safety. Focus groups aged 18-59 years who were vaccinated with SARS-CoV-2 vaccine in Hefei from 15 December 2020 to 10 February 2021 were observed. The incidence, types and severity of adverse reactions after vaccination were descriptively analyzed. Results A total of 18 574 people were effectively observed, and 33 433 doses of SARS-CoV-2 vaccine were inoculated. 713 cases of general adverse reactions occurred, with an incidence of 2.13%. The incidence of adverse reactions in the first dose was 2.57%, which was higher than that in the second dose (1.58%, χ²=38.92, P < 0.001). There was no statistical significance in the incidence of general adverse reactions of inactivated vaccine produced by the two companies (χ²=3.08, P=0.082). Among the adverse events such as redness and swelling at the injection site, induration at the injection site, and fever, the incidence of grade 1, 2 and 3 adverse events were 0.65%, 1.42%, and 0.06%, but there were no ≥ grade 4, rare and extremely rare adverse events. Conclusion Domestic inactivated SARS-CoV-2 vaccine (Vero cells) is great safe.
- SARS-CoV-2,
- Inactivated vaccine,
- Safety

FullText(HTML)

References(14)

References

[1]	World Health Organization. Coronavious disease(COVID-2019) press briefings[EB/OL]. (2020-03-11)[2021-02-22]. https://www.who.int/emergencies/diseases/novel-conronvious-2019/media-resources/press-briefings.
[2]	World Health Organization. Coronavious disease(COVID-2019) Situation Report[EB/OL]. (2021-02-12)[2021-02-22]. https://www.who.int/emergencies/diseases/novel-conronvious-2019.
[3]	刘元宝, 江湖大川, 李靖欣, 等. 疫苗接种对中国传染病防控事业的巨大贡献[J]. 中华疾病控制杂志, 2019, 23(8): 890-893. DOI: 10.16462/j.cnki.zhjbkz.2019.08.002. Liu YB, Jiang HDC, Li JX, et al. The great contribution of vaccination to the prevention and control of infectious diseases in China[J]. Chin J Dis Control Prev, 2019, 23(8): 890-893. DOI: 10.16462/j.cnki.zhjbkz.2019.08.002.
[4]	中华预防医学会, 中华预防医学会疫苗与免疫分会. 新型冠状病毒流行期间预防接种参考指引(第一版)[S]. 2020. Chinese Preventive Medicine Association, China Preventive Medicine Association Vaccine and Immunology Branch. COVID-19 pandemic guidelines (First Edition)[S]. 2020.
[5]	国家食品药品监督管理总局. 关于印发预防用疫苗临床前研究技术指导原则的通知[Z]. 国食药监注[2010]140号. State Food and Drug Administration. Notice on printing and distributing technical guidelines for preclinical research of preventive vaccines[Z]. Gsyjz[2010]No. 140.
[6]	Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials[J]. JAMA, 2020, 324(10): 1-10. DOI: 10.1001/jama.2020.15543.
[7]	World Health Organization. DRAFT landscape of COVID-19 candidate vaccines[EB/OL]. (2021-01-07)[2021-02-22]. https://www.who.int/publications/m/item/draft-landscape-of-COVID-19-candidate-vaccines.
[8]	Mulligan MJ. An inactivated virus candidate vaccine to prevent COVID-19[J]. JAMA, 2020, 324(10): 943-945. DOI: 10.19485/j.cnki.issn2096-5087.2021.02.009.
[9]	Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report[EB/OL]. (2021-01-07)[2021-02-22]. https://www.researchgate.net/publication/343630942 COVID-19 Vaccine A comprehensive status report.
[10]	Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a ran-domised, double-blind, placebo-controlled, phase 1/2 trial[J]. Lancet Infect Dis, 2020, 21(1): 39-51. DOI: 10.1016/s1473-3099(20)30831-8.
[11]	Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial[EB/OL]. (2020-11-17)[2021-01-07]. https://www.sciencedirect.com/science/article/pii/S1473309920308434.
[12]	国务院新闻办公室. 国务院联防联控机制举行新冠病毒疫苗附条件上市及相关工作情况发布会[EB/OL]. (2021-01-07)[2021-02-22]. http://www.scio.gov.cn/xwfbh/xwbfbh/wqfbh/42311/44679/index.htm. Information Office of the State Council. Joint prevention and control mechanism of the State Council held a press conference on conditional marketing and related work of COVID-19 vaccine[EB/OL]. (2021-01-07)[2021-02-22]. http://www.scio.gov.cn/xwfbh/xwbfbh/wqfbh/42311/44679/index.htm.
[13]	高文静, 王波, 李立明, 等. 新型冠状病毒肺炎流行现状及应对策略进展[J]. 中华流行病学杂志, 2021, 42(1): 22-26. DOI: 10.3760/cma.j.cn112338-20201026-01275. Gao WJ, Wang B, Li LM, et al. Current status of COVID-19 pandemic and progress in response strategy[J]. Chin J Epidemiol, 2021, 42(1): 22-26. DOI: 10.3760/cma.j.cn112338-20201026-01275.
[14]	郭岩, 黄旸木, 黄捷, 等. 新型冠状病毒肺炎疫情的全球流行现状和其对中国的影响及政策建议[J]. 中华流行病学杂志, 2020, 41(5): 642-647. DOI: 10.3760/cma.j.cn112338-20200301-00222. Guo Y, Huang YM, Huang J, et al. COVID-19 pandemic: global epidemiological trends and Chinese subsequent preparedness and responses[J]. Chin J Epidemiol, 2020, 41(5): 642-647. DOI: 10.3760/cma.j.cn112338-20200301-00222.